Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

LY364947

SKU: orb1306643

Description

LY-364947 (HTS466284) is a selective, ATP-competitive small molecule inhibitor targeting the TGF-β type I receptor kinase (ALK5). It is widely utilized in biochemical and cellular assays to investigate TGF-β signaling pathways in cancer, fibrosis, and developmental biology research, demonstrating activity in both in vitro and in vivo models.

Research Area

Immunology & Inflammation, Neuroscience, Stem Cell & Developmental Biology

Images & Validation

Key Properties

CAS Number396129-53-6
MW272.3
Purity>98%
FormulaC17H12N4
SMILESN1C=C(C(=N1)C1=NC=CC=C1)C1=CC=NC2=CC=CC=C12
TargetKinase
SolubilitySoluble in DMSO (75 mg/ml)

Bioactivity

Target IC50
RIPK2:0.11 μM|TGFβRII:0.4 μM|MLK7K:1.4 μM|CK1δ:0.22 μM|TGFβRI:59 nM
In Vivo
At a concentration as low as 0.25 μM, LY364947 enhances the xVent2-lux BMP4 response in NMuMG cells by 30%. At 2 μM, it prevents TGF-β-induced epithelial-mesenchymal transition (EMT) in NMuMG cells. A 3 μM dose of LY364947, after 24 hours of treatment, induces the expression of Prox1 and LYVE-1 in nearly all HDLECs. LY364947 promotes the nuclear export of Foxo3a and is characterized by low Smad2/3 and high Akt phosphorylation levels in leukemia-positive cells. When co-cultured with OP-9 stromal cells, LY364947 (at concentrations <20 μM) inhibits the colony-forming ability of leukemia-initiating cells. Acting as an ATP-competitive, tight-binding inhibitor, LY364947 inhibits P-Smad3 phosphorylation through TGFβR-I kinase with a Ki of 28 nM and inhibits Smad2 phosphorylation in NMuMG cells in vivo with an IC50 of 135 nM.
In Vitro
Administering 1 mg/kg i.p. of LY364947 significantly enhances the LYVE-1-positive regions within the tumor tissues in a BxPC3 pancreatic cancer xenograft model. Similarly, 25 mg/kg i.p. of LY364947 markedly increases LYVE-1-positive areas in a chronic peritonitis mouse model, indicating accelerated lymphangiogenesis. Additionally, LY364947 (25 mg/kg) increases p-Akt levels and decreases nuclear Foxo3a in leukemia-initiating cells in mice infected with CML.

Storage & Handling

StorageRT
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

HTS-466284

Similar Products

  • LY-364947 [orb1225117]

    >98% (HPLC)

    396129-53-6

    272.3

    C17H12N4

    1 g, 500 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

LY364947 (orb1306643)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 210.00
25 mg
$ 480.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry